287 related articles for article (PubMed ID: 35181160)
21. Treatment of Systemic Sclerosis-associated Interstitial Lung Disease: Evidence-based Recommendations. An Official American Thoracic Society Clinical Practice Guideline.
Raghu G; Montesi SB; Silver RM; Hossain T; Macrea M; Herman D; Barnes H; Adegunsoye A; Azuma A; Chung L; Gardner GC; Highland KB; Hudson M; Kaner RJ; Kolb M; Scholand MB; Steen V; Thomson CC; Volkmann ER; Wigley FM; Burlile D; Kemper KA; Knight SL; Ghazipura M
Am J Respir Crit Care Med; 2024 Jan; 209(2):137-152. PubMed ID: 37772985
[No Abstract] [Full Text] [Related]
22. [Interstitial lung disease in systemic sclerosis].
Mouthon L; Berezné A; Brauner M; Kambouchner M; Guillevin L; Valeyre D
Presse Med; 2006 Dec; 35(12 Pt 2):1943-51. PubMed ID: 17159721
[TBL] [Abstract][Full Text] [Related]
23. Learnings from clinical trials in patients with connective tissue disease-associated interstitial lung disease.
Higuero Sevilla JP; Memon A; Hinchcliff M
Arthritis Res Ther; 2023 Jul; 25(1):118. PubMed ID: 37422652
[TBL] [Abstract][Full Text] [Related]
24. Detection and Monitoring of Interstitial Lung Disease in Patients with Systemic Sclerosis.
Khanna SA; Nance JW; Suliman SA
Curr Rheumatol Rep; 2022 May; 24(5):166-173. PubMed ID: 35499699
[TBL] [Abstract][Full Text] [Related]
25. Recent innovations in the screening and diagnosis of systemic sclerosis-associated interstitial lung disease.
Makol A; Nagaraja V; Amadi C; Pugashetti JV; Caoili E; Khanna D
Expert Rev Clin Immunol; 2023 Jun; 19(6):613-626. PubMed ID: 36999788
[TBL] [Abstract][Full Text] [Related]
26. Interstitial Lung Disease: How Should Therapeutics Be Implemented?
Bruni C; Campochiaro C; de Vries-Bouwstra JK
Rheum Dis Clin North Am; 2023 May; 49(2):279-293. PubMed ID: 37028835
[TBL] [Abstract][Full Text] [Related]
27. Systemic Sclerosis Associated Interstitial Lung Disease: A Comprehensive Overview.
Mackintosh JA; Stainer A; Barnett JL; Renzoni EA
Semin Respir Crit Care Med; 2019 Apr; 40(2):208-226. PubMed ID: 31137061
[TBL] [Abstract][Full Text] [Related]
28. The need for a holistic approach for SSc-ILD - achievements and ambiguity in a devastating disease.
Hoffmann-Vold AM; Allanore Y; Bendstrup E; Bruni C; Distler O; Maher TM; Wijsenbeek M; Kreuter M
Respir Res; 2020 Jul; 21(1):197. PubMed ID: 32703199
[TBL] [Abstract][Full Text] [Related]
29. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
Lamb YN
Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296
[TBL] [Abstract][Full Text] [Related]
30. Where are we going in the management of interstitial lung disease in patients with systemic sclerosis?
Iudici M; Moroncini G; Cipriani P; Giacomelli R; Gabrielli A; Valentini G
Autoimmun Rev; 2015 Jul; 14(7):575-8. PubMed ID: 25709096
[TBL] [Abstract][Full Text] [Related]
31. Management of systemic sclerosis: the first five years.
Roofeh D; Khanna D
Curr Opin Rheumatol; 2020 May; 32(3):228-237. PubMed ID: 32205570
[TBL] [Abstract][Full Text] [Related]
32. Tracking Impact of Interstitial Lung Disease in Systemic Sclerosis in a Complete Nationwide Cohort.
Hoffmann-Vold AM; Fretheim H; Halse AK; Seip M; Bitter H; Wallenius M; Garen T; Salberg A; Brunborg C; Midtvedt Ø; Lund MB; Aaløkken TM; Molberg Ø
Am J Respir Crit Care Med; 2019 Nov; 200(10):1258-1266. PubMed ID: 31310156
[No Abstract] [Full Text] [Related]
33. [Treatment of systemic sclerosis-associated interstitial lung disease].
Prasse A; Bonella F; Müller-Ladner U; Witte T; Hunzelmann N; Distler J
Z Rheumatol; 2020 Apr; 79(3):294-303. PubMed ID: 31754786
[TBL] [Abstract][Full Text] [Related]
34. Mycophenolate mofetil as a therapeutic agent for interstitial lung diseases in systemic sclerosis.
Ueda T; Sakagami T; Kikuchi T; Takada T
Respir Investig; 2018 Jan; 56(1):14-20. PubMed ID: 29325675
[TBL] [Abstract][Full Text] [Related]
35. The effect of nintedanib versus mycophenolate mofetil in the Fra2 mouse model of systemic sclerosis-associated interstitial lung disease.
Wollin L; Trinh-Minh T; Zhang Y; Distler JHW
Clin Exp Rheumatol; 2021; 39 Suppl 131(4):134-141. PubMed ID: 33886452
[TBL] [Abstract][Full Text] [Related]
36. Economic Burden and Management of Systemic Sclerosis-Associated Interstitial Lung Disease in 8 European Countries: The BUILDup Delphi Consensus Study.
Davidsen JR; Miedema J; Wuyts W; Kilpeläinen M; Papiris S; Manali E; Robalo Cordeiro C; Morais A; Pérez M; Asijee G; Cendoya D; Soulard S
Adv Ther; 2021 Jan; 38(1):521-540. PubMed ID: 33156462
[TBL] [Abstract][Full Text] [Related]
37. Interstitial lung disease in systemic sclerosis: current and future treatment.
Giacomelli R; Liakouli V; Berardicurti O; Ruscitti P; Di Benedetto P; Carubbi F; Guggino G; Di Bartolomeo S; Ciccia F; Triolo G; Cipriani P
Rheumatol Int; 2017 Jun; 37(6):853-863. PubMed ID: 28063071
[TBL] [Abstract][Full Text] [Related]
38. [New developments in systemic sclerosis-associated interstitial lung disease].
Humair G; Daccord C; Beigelman-Aubry C; Lazor R
Rev Med Suisse; 2020 Nov; 16(715):2218-2223. PubMed ID: 33206479
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial.
Highland KB; Distler O; Kuwana M; Allanore Y; Assassi S; Azuma A; Bourdin A; Denton CP; Distler JHW; Hoffmann-Vold AM; Khanna D; Mayes MD; Raghu G; Vonk MC; Gahlemann M; Clerisme-Beaty E; Girard M; Stowasser S; Zoz D; Maher TM;
Lancet Respir Med; 2021 Jan; 9(1):96-106. PubMed ID: 33412120
[TBL] [Abstract][Full Text] [Related]
40. Antifibrotic efficacy of nintedanib in a cellular model of systemic sclerosis-associated interstitial lung disease.
Atanelishvili I; Akter T; Noguchi A; Vuyiv O; Wollin L; Silver RM; Bogatkevich GS
Clin Exp Rheumatol; 2019; 37 Suppl 119(4):115-124. PubMed ID: 31573469
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
